All News
Filter News
Found 499 articles
-
ChineseInvestors.com, Inc. Announces Record Revenues for Q3 Fiscal Year 2019
4/17/2019
ChineseInvestors.com, Inc. (OTCQB: CIIX) ("CIIX" or "the Company"), an established financial news and investment portal, and a leading industrial hemp retailer for the Chinese-speaking community, today announced its financial and operational summary for the Third Quarter of its Fiscal Year 2019.
-
IO Biotech Presents Data on an Immunomodulatory CCL22-based Vaccine at the American Association for Cancer Research Annual Meeting 2019
4/1/2019
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win® technology, presented preclinical data on the therapeutic potential of an immunomodulatory CCL22-based vaccine
-
ChineseInvestors.com, Inc.'s Wholly Foreign-Owned Enterprise CBD Biotechnology Co. Ltd. Participates in the 29th Vietnam Expo 2019 to Develop New Markets for its Industrial Hemp Product Line
4/1/2019
ChineseInvestors.com, Inc. recently announced that its wholly owned foreign enterprise, CBD Biotechnology Co. Ltd. ("CBD Biotech"), will participate in the 29th Vietnam International Trade Fair (Vietnam Expo) at the Hanoi International Exhibition Center (ICE) being held on April 10-13, 2019 in Hanoi.
-
BioSpace takes a quick look at some of the news coming from biotech and pharma companies from across Europe and Asia.
-
NeoPhore appoints Dr John Haurum as Non-Executive Director
3/20/2019
Former F-star CEO joins the Board of Directors
-
Bristol-Myers Squibb Files Investor Presentation and Board of Directors Sends Letter to Shareholders Regarding Pending Transaction with Celgene
3/6/2019
Board and Management Team Conducted a Robust Process and Diligence and Are Committed to a Successful Integration
-
ChineseInvestors.com, Inc.'s Wholly Owned Subsidiary ChineseHempOil.com, Inc. Announces Rebranding of its Consumer Product Line, Now the opt™ Brand
2/19/2019
New Line of Consumer Products to Feature the opt2mist Line of Vitamin Sprays Launching Later this Month on a Single, Consolidated e-Commerce Site for One-Stop Shopping at www.365CWC.com
-
NanOlogy Chief Medical Officer on Panel to Discuss Next Wave of Innovation in IO Therapy at BIO CEO & Investor Conference
2/5/2019
Company’s submicron particle investigational drugs show promise as immune system booster
-
NeoImmuneTech Receives Authorization to Proceed from the FDA for IND Application to Evaluate Hyleukin-7 in Combination with a PD-L1 Inhibitor in Advanced High-Risk Skin Cancers
1/16/2019
The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of Hyleukin-7 in combination with Tecentriq in approximately 80 patients with anti-PD-(L)1 naïve or relapsed/refractory high-risk skin cancers.
-
CENTOGENE Provides Corporate and Business Unit Update
1/8/2019
2018 highlights include expansion to U.S., new partnerships with leading pharmaceutical companies, and growth of diagnostic testing portfolio for rare diseases - driving momentum into 2019
-
Healthcare Executive from Amazon Joins binx health Board of Directors
1/7/2019
binx health today announced that it has appointed Samar Parikh to its Board of Directors.
-
ChineseInvestors.com, Inc. Engages Boustead Securities, LLC for Planned IPO of its Wholly Owned Subsidiary, CBD Biotech
12/27/2018
ChineseInvestors.com, Inc. oday announced that it has retained Boustead Securities, LLC as underwriter for the planned Initial Public Offering ("IPO") of its wholly owned foreign enterprise, CBD Biotech Co. Ltd. ("CBD Biotech"), concurrently with a listing on a national securities exchange.
-
binx health's Rapid, Point-of-Care Platform Shows Clinical Strength for Chlamydia Testing in Study by Johns Hopkins University and National Institutes of Health
12/18/2018
Patients wondering if they have the sexually transmitted infections ("STI") chlamydia or gonorrhea may soon be able to get the results in about 30 minutes, according to new research funded through the National Institutes of Health.
-
F-star to Disclose Targets and Preclinical Data on New Agonist Bispecific Antibody Programmes
11/1/2018
Developed to address current patient needs that are not well-served by checkpoint monotherapies or combinations of monotherapies
-
Innate Pharma strengthens and expands its oncology development collaboration with AstraZeneca
10/23/2018
Innate Pharma SA (“Innate” - Euronext Paris: FR0010331421 – IPH), today announced a new multi-term agreement with AstraZeneca, and its global biologics research and development arm MedImmune
-
Almac Group Launches claraT - A Unique, Software-driven Gene Expression Report
10/19/2018
Saving oncology researchers valuable time, whilst maximising the understanding of their dataset
-
F-star Appoints Dr Eliot Forster as Chief Executive Officer
10/15/2018
F-star today announced the appointment of Dr Eliot Forster as Chief Executive Officer. Dr Forster succeeds former CEO Dr John Haurum.
-
Atlas Genetics Announces Company Rebranding, Changes Name To Binx Health
10/8/2018
Company charts expanded direction and names new key additions
-
e-therapeutics plc Interim Financial Results for the six months ended 31 July 2018
10/4/2018
e-therapeutics plc announces its interim results for the six months ended 31 July 2018.
-
IO Biotech announces first patient dosed in global phase I/II clinical trial for the first-line treatment of patients with metastatic non-small cell lung cancer
9/27/2018
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win® technology, announces that the first patient has received the first dose in an international Phase I/II clinical trial studying the investigational candidate IO102 in combination with KEYTRUDA® (pembrolizumab) for patients with non-small cell lung cancer (NSCLC) – NCT03562871.